Aemetis (NASDAQ:AMTX) Raised to Sell at StockNews.com

StockNews.com upgraded shares of Aemetis (NASDAQ:AMTX) to a sell rating in a research note issued to investors on Wednesday morning.

A number of other research analysts have also recently issued reports on the stock. HC Wainwright reissued a buy rating and set a $28.00 price target on shares of Aemetis in a research report on Friday, May 10th. Truist Financial reissued a hold rating and set a $4.00 price target (up from $3.50) on shares of Aemetis in a research report on Monday, May 13th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of Hold and an average target price of $12.13.

Aemetis Trading Down 6.4 %

NASDAQ:AMTX opened at $2.49 on Wednesday. The company has a 50-day moving average price of $3.26 and a 200-day moving average price of $3.69. Aemetis has a 12 month low of $2.29 and a 12 month high of $7.82. The stock has a market cap of $110.55 million, a price-to-earnings ratio of -2.13 and a beta of 1.32.

Aemetis (NASDAQ:AMTX) last posted its earnings results on Thursday, August 1st. The specialty chemicals company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.25). The firm had revenue of $66.56 million for the quarter, compared to analysts’ expectations of $75.37 million. During the same period last year, the company posted ($0.68) earnings per share. Equities analysts forecast that Aemetis will post -1.59 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director John R. Block sold 51,580 shares of Aemetis stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $3.49, for a total value of $180,014.20. Following the completion of the sale, the director now directly owns 14,001 shares in the company, valued at $48,863.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 14.34% of the company’s stock.

Institutional Trading of Aemetis

A number of large investors have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new stake in Aemetis during the first quarter valued at approximately $60,000. State Board of Administration of Florida Retirement System bought a new stake in Aemetis during the first quarter valued at approximately $84,000. Rhumbline Advisers grew its position in Aemetis by 2,837.1% during the second quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock valued at $157,000 after buying an additional 50,528 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in Aemetis during the second quarter valued at approximately $306,000. 27.02% of the stock is currently owned by institutional investors.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.